Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
Sponsor: Hypoxyprobe
Listed as NCT04658303, this observational or N/A phase trial focuses on Melanoma and remains actively recruiting participants. Sponsored by Hypoxyprobe, it has been updated 11 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Jun 2025 — Present [monthly]
Recruiting
-
Sep 2024 — Jun 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Recruiting
-
May 2023 — Jun 2024 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Apr 2022 — May 2023 [monthly]
Recruiting
Status: Suspended → Recruiting
-
Dec 2021 — Apr 2022 [monthly]
Suspended
-
May 2021 — Dec 2021 [monthly]
Suspended
Status: Recruiting → Suspended
-
Mar 2021 — May 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Not Yet Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hypoxyprobe
- Yana Najjar
For direct contact, visit the study record on ClinicalTrials.gov .